Harrow Joins Apexus’ 340B Prime Vendor Program to Expand Access to IHEEZO and Other Essential Eyecare Products
NASHVILLE, Tenn. - Harrow, a prominent eyecare pharmaceutical company in North America, has officially partnered with Apexus, a leading organization in the healthcare industry, to include their innovative product, IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, in the renowned 340B Prime Vendor Program. This collaboration aims to provide broader access to IHEEZO and other key Harrow products, effective July 1, 2024.
IHEEZO, specially formulated for ocular anesthesia, offers a low-viscosity topical ocular anesthetic gel that ensures reliable efficacy while maintaining a proven safety profile. Its simple administration further enhances its practicality in various clinical settings. With the inclusion of IHEEZO in the 340B Prime Vendor Program, healthcare providers across the nation will be able to procure this essential eyecare product more conveniently and at cost-effective prices.
The 340B Prime Vendor Program, administered by Apexus, serves as a crucial resource for eligible safety-net healthcare facilities, such as hospitals, community health centers, and clinics. This program allows these organizations to access various pharmaceutical products, medical supplies, and services at significantly discounted prices, enabling them to better serve their patients and communities.
Harrow’s decision to join the 340B Prime Vendor Program demonstrates their commitment to expanding access to critical eyecare medication for vulnerable populations. By partnering with Apexus, Harrow ensures that their products, including IHEEZO, will be readily available to safety-net healthcare providers nationwide, ultimately improving patient outcomes and promoting eye health on a broader scale.
Inclusion in the 340B Prime Vendor Program marks a significant milestone for Harrow, stated the company’s spokesperson. We are incredibly proud to contribute to the well-being of underserved communities through this partnership with Apexus. We firmly believe that by making IHEEZO and other essential Harrow products easily accessible, we can positively impact the quality of eyecare services provided to those who need it most.
This collaboration between Harrow and Apexus highlights the dedication of both organizations to advancing accessibility and affordability within the healthcare landscape. By leveraging the reach and influence of the 340B Prime Vendor Program, they aim to bridge the gap between eyecare products and underserved communities, ensuring that everyone has an equal opportunity to access the vital medications they require.
As we move towards July 1, 2024, the implementation of this partnership between Harrow and Apexus will undoubtedly revolutionize the availability and distribution of essential eyecare products through the 340B Prime Vendor Program. Through this collective effort, the future looks brighter for those in need of quality ocular anesthesia and other critical Harrow products, reaffirming the commitment of both organizations to prioritize the well-being of patients across the nation.
Comments